

ANTEGENES

Personalized genetics-based precision prevention of common cancers

We are looking for

- Partners for implementation of our tests (medical companies, laboratories, healthcare providers, telemedicine providers)
- Public or private healthcare organizations for cancer prevention and screening programs
- Clinical implementation research partners

Target markets

Global

Want to know more?

Founder & CEO Dr Peeter Padrik
peeter.padrik@antegenes.com
antegenes.com

OVERVIEW

Antegenes is an international pioneer of precision preventive medicine, aiming to use personal genetic information to reduce the severity and mortality due to common cancers. As our individual cancer risks are very different, prevention and screening of cancers must be much more precise and efficient than currently.

Antegenes develops and implements advanced genetic tests based on polygenic risk scores technology to enable precision prevention. We inform individuals and their doctors about their genetic cancer risks and provide actionable medical recommendations that reduce the likelihood, severity and mortality of common cancers.

Antegenes has brought innovative CE-marked genetic tests relying on polygenic risk scores (in vitro medical devices, 98/79/EC) into clinical use:

- AnteBC – for breast cancer
- AntePC – for prostate cancer
- AnteCRC – for colorectal cancer
- AnteMEL – for melanoma

Based on our tests we have created and implemented genetics-based precision prevention programs.

Antegenes' products are created scientifically with laboratory and clinical validity and clinical usefulness, which makes them usable in healthcare by a broad range of healthcare professionals and institutions.



- Products are based on peer-reviewed international research and have been evaluated and validated using anonymized population data of the UK Biobank and Estonian Biobank.
- Tests are among the **first CE-marked** in vitro medical device (IVD) level polygenic risk score tests in the world.
- Tests have adaptations for different ethnic backgrounds.
- Our services include development and creation of genetics-based personalized cancer screening programs for different clinical settings and populations.

Antegenes® (est. 2018) is an ISO 13485 certified health-tech company and a registered healthcare service provider (laboratory services; medical genetics, oncology) in Estonia.

